You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
106 Branford and Hughes<br />
and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112,<br />
831–843.<br />
24. Corbin, A. S., Buchdunger, E., Pascal, F., and Druker, B. J. (2002) Analysis of the<br />
structural basis of specificity of inhibition of the Abl kinase by STI571. J. Biol.<br />
Chem. 277, 32,214–32,219.<br />
25. Corbin, A. S., La Rosee, P., Stoffregen, E. P., Druker, B. J., and Deininger, M. W.<br />
(2003) Several Bcr-Abl kinase domain mutants associated with imatinib mesylate<br />
resistance remain sensitive to imatinib. Blood 101, 4611–4614.<br />
26. Branford, S., Rudzki, Z., Miller, B., et al. (2003) Mutations in the catalytic core<br />
(P-loop) of the BCR-ABL kinase domain of imatinib-treated chronic myeloid leukemia<br />
patients in chronic phase are strongly associated with imminent progression<br />
to blast crisis [abstract]. Blood 102, 71a.<br />
27. Shah, N. P. and Sawyers, C. L. (2003) Mechanisms of resistance to STI571 in<br />
Philadelphia chromosome-associated leukemias. Oncogene 22, 7389–7395.<br />
28. Branford, S., Rudzki, Z., Walsh, S., et al. (2002) High frequency of point mutations<br />
clustered within the adenosine triphosphate-binding region of BCR/ABL in<br />
patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia<br />
who develop imatinib (STI571) resistance. Blood 99, 3472–3475.<br />
29. Branford, S., Hughes, T. P. and Rudzki, Z. (1999) Monitoring chronic myeloid<br />
leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative<br />
to bone marrow cytogenetics. Br. J. Haematol. 107, 587–599.
Change language